These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
233 related articles for article (PubMed ID: 34439918)
21. Pemetrexed-based chemotherapy in advanced lung adenocarcinoma patients with different EGFR genotypes. Jiang X; Yang B; Lu J; Zhan Z; Li K; Ren X Tumour Biol; 2015 Feb; 36(2):861-9. PubMed ID: 25301443 [TBL] [Abstract][Full Text] [Related]
22. Cost effectiveness of first-line pemetrexed plus platinum compared with other regimens in the treatment of patients with nonsquamous non-small cell lung cancer in the US outpatient setting. Shah M; Winfree KB; Peterson P; Gruschkus SK; Eaddy M; Green MR Lung Cancer; 2013 Oct; 82(1):121-7. PubMed ID: 23973203 [TBL] [Abstract][Full Text] [Related]
23. [Association between the ALK Gene Status and the Efficacy of First-line Pemetrexed Chemotherapy in Patients with Advanced Lung Adenocarcinoma]. Chen M; Cao H; Ji Y; Mao Y; Shen S; Li X Zhongguo Fei Ai Za Zhi; 2017 Nov; 20(11):732-736. PubMed ID: 29167001 [TBL] [Abstract][Full Text] [Related]
24. Pembrolizumab plus pemetrexed-platinum for metastatic nonsquamous non-small-cell lung cancer: KEYNOTE-189 Japan Study. Horinouchi H; Nogami N; Saka H; Nishio M; Tokito T; Takahashi T; Kasahara K; Hattori Y; Ichihara E; Adachi N; Noguchi K; Souza F; Kurata T Cancer Sci; 2021 Aug; 112(8):3255-3265. PubMed ID: 34036692 [TBL] [Abstract][Full Text] [Related]
25. An Open-Label Randomized Controlled Trial Comparing the Efficacy and Safety of Pemetrexed-Carboplatin versus (Weekly) Paclitaxel-Carboplatin as First-Line Chemotherapy in Advanced Non-Squamous Non-Small Cell Lung Cancer. Yadav A; Malik PS; Khurana S; Jain D; Vishnubhatla S; Yadav M; Pathy S; Mohan A; Kumar L Oncology; 2021; 99(6):389-396. PubMed ID: 33735884 [TBL] [Abstract][Full Text] [Related]
26. Quality of life in patients with advanced non-small-cell lung cancer given maintenance treatment with pemetrexed versus placebo (H3E-MC-JMEN): results from a randomised, double-blind, phase 3 study. Belani CP; Brodowicz T; Ciuleanu TE; Krzakowski M; Yang SH; Franke F; Cucevic B; Madhavan J; Santoro A; Ramlau R; Liepa AM; Visseren-Grul C; Peterson P; John WJ; Zielinski CC Lancet Oncol; 2012 Mar; 13(3):292-9. PubMed ID: 22336221 [TBL] [Abstract][Full Text] [Related]
27. Practice Patterns and Outcomes for Pemetrexed Plus Platinum Doublet as Neoadjuvant Chemotherapy in Adenocarcinomas of Lung: Looking Beyond the Usual Paradigm. Noronha V; Zanwar S; Joshi A; Patil VM; Mahajan A; Janu A; Agarwal JP; Bhargava P; Kapoor A; Prabhash K Clin Oncol (R Coll Radiol); 2018 Jan; 30(1):23-29. PubMed ID: 29239731 [TBL] [Abstract][Full Text] [Related]
28. Crizotinib in patients with anaplastic lymphoma kinase-positive advanced non-small cell lung cancer versus chemotherapy as a first-line treatment. Zhou J; Zheng J; Zhang X; Zhao J; Zhu Y; Shen Q; Wang Y; Sun K; Zhang Z; Pan Z; Shen Y; Zhou J BMC Cancer; 2018 Jan; 18(1):10. PubMed ID: 29298713 [TBL] [Abstract][Full Text] [Related]
29. First-iGAP: A Randomized Placebo-Controlled Phase II Study of First-line Intercalated Gefitinib and Pemetrexed-Cisplatin Chemotherapy for Never-Smoker Lung Adenocarcinoma Patients. Lee Y; Kim HY; Nam BH; Lee GK; Kim HT; Han JY; An HJ; Lee JS Clin Lung Cancer; 2020 Nov; 21(6):e572-e582. PubMed ID: 32605893 [TBL] [Abstract][Full Text] [Related]
30. Elderly subset analysis of randomized phase III study comparing pemetrexed plus carboplatin with docetaxel plus carboplatin as first-line treatment for patients with locally advanced or metastatic non-small cell lung cancer. Pereira JR; Cheng R; Orlando M; Kim JH; Barraclough H Drugs R D; 2013 Dec; 13(4):289-96. PubMed ID: 24277116 [TBL] [Abstract][Full Text] [Related]
31. Efficacy of pemetrexed and carboplatin with or without bevacizumab in lung adenocarcinoma patients with EGFR non-T790M mutations after progression on first-line EGFR-tyrosine kinase inhibitors. Jiang Z; Zhang Y; Yang Y; Yue Z; Pan Z Thorac Cancer; 2018 Sep; 9(9):1151-1155. PubMed ID: 30027579 [TBL] [Abstract][Full Text] [Related]
32. A Randomized, Open-Label Phase II Trial of Volasertib as Monotherapy and in Combination With Standard-Dose Pemetrexed Compared With Pemetrexed Monotherapy in Second-Line Treatment for Non-Small-Cell Lung Cancer. Ellis PM; Leighl NB; Hirsh V; Reaume MN; Blais N; Wierzbicki R; Sadrolhefazi B; Gu Y; Liu D; Pilz K; Chu Q Clin Lung Cancer; 2015 Nov; 16(6):457-65. PubMed ID: 26100229 [TBL] [Abstract][Full Text] [Related]
33. [Comparison of the efficacy of second line EGFR TKIs followed by third line pemetrexed or the reverse sequence in the treatment of advanced lung adenocarcinoma]. Zhang RX; Cai DY; Hong TT; Wu XH; Hua D Zhonghua Zhong Liu Za Zhi; 2012 Feb; 34(2):147-51. PubMed ID: 22780936 [TBL] [Abstract][Full Text] [Related]
34. Maintenance therapy with pemetrexed plus best supportive care versus placebo plus best supportive care after induction therapy with pemetrexed plus cisplatin for advanced non-squamous non-small-cell lung cancer (PARAMOUNT): a double-blind, phase 3, randomised controlled trial. Paz-Ares L; de Marinis F; Dediu M; Thomas M; Pujol JL; Bidoli P; Molinier O; Sahoo TP; Laack E; Reck M; Corral J; Melemed S; John W; Chouaki N; Zimmermann AH; Visseren-Grul C; Gridelli C Lancet Oncol; 2012 Mar; 13(3):247-55. PubMed ID: 22341744 [TBL] [Abstract][Full Text] [Related]
35. Sequential Administration of EGFR-TKI and Pemetrexed Achieved a Long Duration of Response in Advanced NSCLC Patients with EGFR-mutant Tumours. Yue-Yun C; Ye H; Yang F; Qing L; Pan-Pan L; Zhen-Yu D Asian Pac J Cancer Prev; 2019 Aug; 20(8):2415-2420. PubMed ID: 31450915 [TBL] [Abstract][Full Text] [Related]
36. Docetaxel or pemetrexed with or without cetuximab in recurrent or progressive non-small-cell lung cancer after platinum-based therapy: a phase 3, open-label, randomised trial. Kim ES; Neubauer M; Cohn A; Schwartzberg L; Garbo L; Caton J; Robert F; Reynolds C; Katz T; Chittoor S; Simms L; Saxman S Lancet Oncol; 2013 Dec; 14(13):1326-36. PubMed ID: 24231627 [TBL] [Abstract][Full Text] [Related]
37. Potential Benefits of Bevacizumab Combined With Platinum-Based Chemotherapy in Advanced Non-Small-Cell Lung Cancer Patients With EGFR Mutation. Tanaka I; Morise M; Miyazawa A; Kodama Y; Tamiya Y; Gen S; Matsui A; Hase T; Hashimoto N; Sato M; Hasegawa Y Clin Lung Cancer; 2020 May; 21(3):273-280.e4. PubMed ID: 32088115 [TBL] [Abstract][Full Text] [Related]
38. Survival outcome according to KRAS mutation status in newly diagnosed patients with stage IV non-small cell lung cancer treated with platinum doublet chemotherapy. Brady AK; McNeill JD; Judy B; Bauml J; Evans TL; Cohen RB; Langer C; Vachani A; Aggarwal C Oncotarget; 2015 Oct; 6(30):30287-94. PubMed ID: 26471290 [TBL] [Abstract][Full Text] [Related]
39. Pemetrexed Plus Platinum for Patients With Advanced Non-small Cell Lung Cancer and Interstitial Lung Disease. Fujita T; Kuroki T; Hayama N; Shiraishi Y; Amano H; Nakamura M; Hirano S; Tabeta H; Nakamura S In Vivo; 2019; 33(6):2059-2064. PubMed ID: 31662538 [TBL] [Abstract][Full Text] [Related]
40. Comparative Effectiveness of Carboplatin/Pemetrexed With Versus Without Bevacizumab for Advanced Nonsquamous Non-Small Cell Lung Cancer. Bagley SJ; Talento S; Mitra N; Meropol NJ; Cohen RB; Langer CJ; Vachani A J Natl Compr Canc Netw; 2019 May; 17(5):469-477. PubMed ID: 31085759 [TBL] [Abstract][Full Text] [Related] [Previous] [Next] [New Search]